Pigazzi M, Ferrari G, Masetti R, Falini B, Martinolli F, Basso G, Biondi A, Pession A, Cazzaniga G. Low prevalence of IDH1 gene mutation in childhood AML in Italy. Leukemia. 2011; 25(1):173-4.Pigazzi M., Ferrari G., Masetti R., Falini B., Martinolli F., Basso G., et...
尽管NPM1突变是界定白血病病种级的病变,但在白血病风险升高中经常是相对靠后的事件,一般次于诸如DNMT3A、TET2、IDH1和IDH2这些表观遗传学突变。 NPM1 mutations appear to precede FLT3―ITD. AML with mutated NPM1 shows a distinct gene expression profile ...
Other novel treatment strategies include enasidenib, an isocitrate dehydrogenase-2 (IDH2) inhibitor, or ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, which may be useful for adult patients with relapsed or refractory AML who have an IDH2 or an IDH1 mutation, and gemtuzumab ...
We have a couple of other [targets], including IDH1, and we have 2 medications to that target the IDH1 mutation. One is ivosidenib [Tibsovo], and the other is olutasidenib [Rezlidhia], which was approved recently. For IDH2, we have enasidenib [Idhifa]. The other exciting aspect that...
andU2AF1showed significantly lower mutation rates whenTP53was mutated compared to cases with wildtypeTP53(chi-square test;ASXL1:p < 0.001,BCOR: p = 0.006,EZH2: p = 0.030,SRSF2: p < 0.001,U2AF1: p = 0.014, Supplementary Fig.2). Mutation rates ofIDH1andIDH2were ...
一个由33个MDS/AML基因(ASXL1(第12外显子)、BCOR(全部外显子)、CALR(第9外显子)、CBL(第7+8+9外显子)、CEBPA(全部)、CSF3R(第14 - 17外显子)、DNMT3A(全部)、ETV6(全部)、EZH2(全部)、FLT3(第14+15+20外显子)、GATA2(全部)、GNAS(第8+9外显子)、IDH1(第4外显子)、IDH2(第4外显子)、...
MolecularclassesofAMLandconcurrentgenemutations 重现性AML基因突变具有不同的功能 ©2014.PublishedbyTheCompanyofBiologistsLtd 突变对AML预后的影响 •RAD21和/或NRAScodon12/13mutations预后好。•NPM1mutations合并IDH1/IDH2mutations容易复发。•NPM1合并DNMT3A/FLT3ITD生存期短，复发相关性死亡 高。•NPM1...
沈玉雷老师也曾分享过一例形态和流式都酷像APL的AML伴IDH1突变病例,但基因并不支持APL伴PML-RARA及RARA变异型。 (三)形态特点、染色体核型像APL,但融合基因不支持APL 朱建锋老师在其公众号分享过一篇名为“遗传学伴t(15;17)易位一定是APL吗?”的文章,该文章[12]介绍的病例临床表现和流式免疫表型都类似APL,染色...
IDH1 mutation: IDH2 mutation: NPM1 mutation: CEBPA mutation: FLT3 internal tandem duplication mutation: FLT3 tyrosine kinase domain mutation: NRAS mutation: KRAS mutation: EVI1 expression: Please note: the generated p value does not include correction for multiple hypothesis testing by...
2mutation was an independent favorable prognostic factor for 4-year overall survival (OS) in total NK-AML population (p = 0.03, censoring at allotransplant). We next evaluated the effect of addition of cladribine to induction regimen on the patients’ outcome according toIDH1/2mutation ...